Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +43.91%
#3 Pons Pons +21.40%
#4 ADO Protocol ADO Protocol +18.01%
#5 Main Street Yield Main Street Yield +17.48%
#6 Collect on Fanable Collect on Fanable +16.09%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.52%
#8 o1.exchange o1.exchange +13.32%
#9 Velvet Velvet +12.38%
#10 Ontology Gas Ontology Gas +12.35%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
DICE Therapeutics, Inc. DICE Therapeutics, Inc.

DICE Therapeutics, Inc.

DICE
Rank in Stocks #9048
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating... DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.
Share Price
$47.55
Last synced: 2023-08-18
Market Cap
$1.10B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade DICE Therapeutics, Inc. (DICE)

Category

Healthcare
P/E ratio for DICE Therapeutics, Inc. (DICE)
P/E ratio as of 2026 TTM: 0
According to DICE Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for DICE Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.